Free Trial

Tempus AI (TEM) Competitors

Tempus AI logo
$71.60 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$68.75 -2.85 (-3.98%)
As of 06:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TEM vs. LH, DGX, GH, BTSG, and FMS

Should you buy Tempus AI stock or one of its competitors? Tempus AI's main competitors and comparable companies include Labcorp (LH), Quest Diagnostics (DGX), Guardant Health (GH), BrightSpring Health Services (BTSG), and Fresenius Medical Care AG & Co. KGaA (FMS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Tempus AI compare to Labcorp?

Labcorp (NYSE:LH) and Tempus AI (NASDAQ:TEM) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, Tempus AI had 1 more articles in the media than Labcorp. MarketBeat recorded 15 mentions for Tempus AI and 14 mentions for Labcorp. Tempus AI's average media sentiment score of 0.65 beat Labcorp's score of 0.34 indicating that Tempus AI is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Labcorp
5 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tempus AI
6 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

Labcorp has a net margin of 6.88% compared to Tempus AI's net margin of -12.54%. Labcorp's return on equity of 17.13% beat Tempus AI's return on equity.

Company Net Margins Return on Equity Return on Assets
Labcorp6.88% 17.13% 7.96%
Tempus AI -12.54%-47.00%-9.44%

Labcorp has higher revenue and earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Labcorp$13.95B2.16$876.50M$12.1930.41
Tempus AI$1.27B10.27-$245.03M-$1.06N/A

Labcorp has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Tempus AI has a beta of 3.61, indicating that its stock price is 261% more volatile than the broader market.

Labcorp presently has a consensus target price of $369.08, suggesting a potential downside of 0.44%. Tempus AI has a consensus target price of $79.37, suggesting a potential upside of 10.85%. Given Tempus AI's higher possible upside, analysts plainly believe Tempus AI is more favorable than Labcorp.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Labcorp
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.83
Tempus AI
1 Sell rating(s)
10 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.45

95.9% of Labcorp shares are owned by institutional investors. Comparatively, 24.2% of Tempus AI shares are owned by institutional investors. 0.8% of Labcorp shares are owned by company insiders. Comparatively, 24.3% of Tempus AI shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Labcorp beats Tempus AI on 10 of the 17 factors compared between the two stocks.

How does Tempus AI compare to Quest Diagnostics?

Tempus AI (NASDAQ:TEM) and Quest Diagnostics (NYSE:DGX) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Tempus AI presently has a consensus target price of $79.37, suggesting a potential upside of 10.85%. Quest Diagnostics has a consensus target price of $248.70, suggesting a potential downside of 4.15%. Given Tempus AI's higher probable upside, equities research analysts clearly believe Tempus AI is more favorable than Quest Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tempus AI
1 Sell rating(s)
10 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.45
Quest Diagnostics
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.56

In the previous week, Quest Diagnostics had 13 more articles in the media than Tempus AI. MarketBeat recorded 28 mentions for Quest Diagnostics and 15 mentions for Tempus AI. Tempus AI's average media sentiment score of 0.65 beat Quest Diagnostics' score of 0.61 indicating that Tempus AI is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tempus AI
6 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Quest Diagnostics
5 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Quest Diagnostics has a net margin of 9.53% compared to Tempus AI's net margin of -12.54%. Quest Diagnostics' return on equity of 16.21% beat Tempus AI's return on equity.

Company Net Margins Return on Equity Return on Assets
Tempus AI-12.54% -47.00% -9.44%
Quest Diagnostics 9.53%16.21%7.41%

Tempus AI has a beta of 3.61, meaning that its stock price is 261% more volatile than the broader market. Comparatively, Quest Diagnostics has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

Quest Diagnostics has higher revenue and earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tempus AI$1.27B10.27-$245.03M-$1.06N/A
Quest Diagnostics$11.04B2.59$992M$10.0425.84

24.2% of Tempus AI shares are held by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are held by institutional investors. 24.3% of Tempus AI shares are held by insiders. Comparatively, 0.9% of Quest Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Quest Diagnostics beats Tempus AI on 11 of the 17 factors compared between the two stocks.

How does Tempus AI compare to Guardant Health?

Tempus AI (NASDAQ:TEM) and Guardant Health (NASDAQ:GH) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

24.2% of Tempus AI shares are owned by institutional investors. Comparatively, 92.6% of Guardant Health shares are owned by institutional investors. 24.3% of Tempus AI shares are owned by insiders. Comparatively, 5.6% of Guardant Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tempus AI currently has a consensus target price of $79.37, indicating a potential upside of 10.85%. Guardant Health has a consensus target price of $190.88, indicating a potential upside of 25.83%. Given Guardant Health's stronger consensus rating and higher probable upside, analysts clearly believe Guardant Health is more favorable than Tempus AI.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tempus AI
1 Sell rating(s)
10 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.45
Guardant Health
1 Sell rating(s)
0 Hold rating(s)
24 Buy rating(s)
1 Strong Buy rating(s)
2.96

Tempus AI has a beta of 3.61, meaning that its stock price is 261% more volatile than the broader market. Comparatively, Guardant Health has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market.

Tempus AI has higher earnings, but lower revenue than Guardant Health. Tempus AI is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tempus AI$1.27B10.27-$245.03M-$1.06N/A
Guardant Health$1.28B16.05-$416.28M-$3.68N/A

In the previous week, Tempus AI had 2 more articles in the media than Guardant Health. MarketBeat recorded 15 mentions for Tempus AI and 13 mentions for Guardant Health. Tempus AI's average media sentiment score of 0.65 beat Guardant Health's score of 0.09 indicating that Tempus AI is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tempus AI
6 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Guardant Health
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

Tempus AI has a net margin of -12.54% compared to Guardant Health's net margin of -37.93%. Guardant Health's return on equity of 0.00% beat Tempus AI's return on equity.

Company Net Margins Return on Equity Return on Assets
Tempus AI-12.54% -47.00% -9.44%
Guardant Health -37.93%N/A -25.03%

Summary

Guardant Health beats Tempus AI on 9 of the 17 factors compared between the two stocks.

How does Tempus AI compare to BrightSpring Health Services?

BrightSpring Health Services (NASDAQ:BTSG) and Tempus AI (NASDAQ:TEM) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

In the previous week, Tempus AI had 9 more articles in the media than BrightSpring Health Services. MarketBeat recorded 15 mentions for Tempus AI and 6 mentions for BrightSpring Health Services. BrightSpring Health Services' average media sentiment score of 1.04 beat Tempus AI's score of 0.65 indicating that BrightSpring Health Services is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BrightSpring Health Services
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tempus AI
6 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

24.2% of Tempus AI shares are held by institutional investors. 2.8% of BrightSpring Health Services shares are held by insiders. Comparatively, 24.3% of Tempus AI shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BrightSpring Health Services has a net margin of 2.69% compared to Tempus AI's net margin of -12.54%. BrightSpring Health Services' return on equity of 18.56% beat Tempus AI's return on equity.

Company Net Margins Return on Equity Return on Assets
BrightSpring Health Services2.69% 18.56% 6.03%
Tempus AI -12.54%-47.00%-9.44%

BrightSpring Health Services has higher revenue and earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than BrightSpring Health Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BrightSpring Health Services$12.91B1.10$190.67M$1.8538.49
Tempus AI$1.27B10.27-$245.03M-$1.06N/A

BrightSpring Health Services currently has a consensus target price of $77.81, indicating a potential upside of 9.27%. Tempus AI has a consensus target price of $79.37, indicating a potential upside of 10.85%. Given Tempus AI's higher possible upside, analysts clearly believe Tempus AI is more favorable than BrightSpring Health Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BrightSpring Health Services
0 Sell rating(s)
0 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
3.11
Tempus AI
1 Sell rating(s)
10 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.45

BrightSpring Health Services has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Tempus AI has a beta of 3.61, suggesting that its stock price is 261% more volatile than the broader market.

Summary

BrightSpring Health Services beats Tempus AI on 11 of the 17 factors compared between the two stocks.

How does Tempus AI compare to Fresenius Medical Care AG & Co. KGaA?

Tempus AI (NASDAQ:TEM) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Tempus AI had 7 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 15 mentions for Tempus AI and 8 mentions for Fresenius Medical Care AG & Co. KGaA. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 0.92 beat Tempus AI's score of 0.65 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tempus AI
6 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Fresenius Medical Care AG & Co. KGaA
7 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tempus AI$1.27B10.27-$245.03M-$1.06N/A
Fresenius Medical Care AG & Co. KGaA$22.20B0.53$1.11B$1.7312.75

Fresenius Medical Care AG & Co. KGaA has a net margin of 4.23% compared to Tempus AI's net margin of -12.54%. Fresenius Medical Care AG & Co. KGaA's return on equity of 9.08% beat Tempus AI's return on equity.

Company Net Margins Return on Equity Return on Assets
Tempus AI-12.54% -47.00% -9.44%
Fresenius Medical Care AG & Co. KGaA 4.23%9.08%4.04%

Tempus AI has a beta of 3.61, suggesting that its share price is 261% more volatile than the broader market. Comparatively, Fresenius Medical Care AG & Co. KGaA has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Tempus AI currently has a consensus price target of $79.37, suggesting a potential upside of 10.85%. Fresenius Medical Care AG & Co. KGaA has a consensus price target of $23.43, suggesting a potential upside of 6.16%. Given Tempus AI's stronger consensus rating and higher probable upside, research analysts plainly believe Tempus AI is more favorable than Fresenius Medical Care AG & Co. KGaA.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tempus AI
1 Sell rating(s)
10 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.45
Fresenius Medical Care AG & Co. KGaA
5 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.58

24.2% of Tempus AI shares are held by institutional investors. Comparatively, 8.4% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. 24.3% of Tempus AI shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Tempus AI and Fresenius Medical Care AG & Co. KGaA tied by winning 8 of the 16 factors compared between the two stocks.

Get Tempus AI News Delivered to You Automatically

Sign up to receive the latest news and ratings for TEM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TEM vs. The Competition

MetricTempus AIHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$13.06B$10.86B$7.90B$12.08B
Dividend YieldN/A2.54%2.47%4.53%
P/E Ratio-67.5536.2734.5930.65
Price / Sales10.272.088.635.73
Price / CashN/A23.2821.0222.32
Price / Book25.943.994.873.95
Net Income-$245.03M$335.01M$3.52B$391.64M
7 Day Performance-15.21%-2.55%-3.24%-2.55%
1 Month Performance10.63%0.01%-1.51%-4.04%
1 Year Performance4.56%21.17%1.43%-5.76%

Tempus AI Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TEM
Tempus AI
2.3 of 5 stars
$71.60
flat
$79.37
+10.8%
+4.6%$13.06B$1.27BN/A3,800
LH
Labcorp
3.0343 of 5 stars
$366.74
+0.9%
$369.08
+0.6%
+38.9%$29.79B$13.95B30.1071,000
DGX
Quest Diagnostics
3.7787 of 5 stars
$256.30
+0.6%
$248.70
-3.0%
+38.8%$28.21B$11.04B25.5457,000
GH
Guardant Health
3.548 of 5 stars
$149.72
-2.4%
$191.00
+27.6%
+60.8%$20.22B$982.02MN/A2,506
BTSG
BrightSpring Health Services
3.6417 of 5 stars
$66.70
+1.3%
$77.81
+16.7%
+122.5%$13.28B$15.25B36.0723,500

Related Companies and Tools


This page (NASDAQ:TEM) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners